Records containing: Medulloblastoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-24Methionine PET/CT Studies In Patients With Cancer
-
CLINICAL_TRIALS study record update · 2026-04-24CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation
-
CLINICAL_TRIALS study record update · 2026-04-24An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
-
CLINICAL_TRIALS study record update · 2026-04-24Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
-
CLINICAL_TRIALS study record update · 2026-04-23CSF Cell-free Tumor DNA (CSF cfDNA) Liquid Biopsies for Pediatric, Adolescent, and Young Adult Patients With Primary Brain Tumors
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-15A Pilot Feasibility and Efficacy (Phase 2) Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
-
CLINICAL_TRIALS study record update · 2026-04-14Single-arm Open-label Phase I/II Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
-
CLINICAL_TRIALS study record update · 2026-04-13Phase I/II Study of Lutathera in Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET
-
CLINICAL_TRIALS study record update · 2026-04-08my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
-
CLINICAL_TRIALS study record update · 2026-04-06A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
-
CLINICAL_TRIALS study record update · 2026-03-24Exploring Outcomes and Risk in Patients With Rare Central Nervous System Tumors
-
CLINICAL_TRIALS study record update · 2026-03-19Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors With and Without MYC or MYCN Amplifications
-
CLINICAL_TRIALS study record update · 2026-03-10Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)
-
CLINICAL_TRIALS study record update · 2026-03-05A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma, Ependymoma or Medulloblastoma
-
CLINICAL_TRIALS study record update · 2026-03-02Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
-
CLINICAL_TRIALS study record update · 2026-02-27Evaluation of Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma
-
CLINICAL_TRIALS study record update · 2026-02-20An Intermediate Expanded Use Trial of DFMO
-
CLINICAL_TRIALS study record update · 2026-02-17A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
-
CLINICAL_TRIALS study record update · 2026-02-12SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
-
CLINICAL_TRIALS study record update · 2026-02-12HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue
-
CLINICAL_TRIALS study record update · 2026-02-05A Phase 1/1b Study of Autologous b7-h3 Chimeric Antigen Receptor t Cells (b7-h3.cd28z.Cart) in Children and Young Adults With Recurrent or Progressive Cns Neoplasms Expressing b7-h3 Target
-
CLINICAL_TRIALS study record update · 2026-01-27Phase I Clinical Trial of GPC2 Chimeric Antigen Receptor T (GPC2-CAR T) Cells for Relapsed or Refractory Medulloblastoma in Children and Young Adults
-
CLINICAL_TRIALS study record update · 2026-01-20Loc3CAR: Locoregional Delivery of B7-H3-specific Chimeric Antigen Receptor Autologous T Cells for Pediatric Patients With Primary CNS Tumors
-
CLINICAL_TRIALS study record update · 2026-01-16PNOC044: Liothyronine (L-T3) in Combination With Bevacizumab, Irinotecan and Temozolomide (BIT) for Progressive or Relapsed Medulloblastoma (Cohort 1) or as Monotherapy for Medulloblastoma With Minimal Residual Disease (Cohort 2)
-
CLINICAL_TRIALS study record update · 2026-01-09Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer